2023 World Conference on Lung Cancer (Posters)-EP08.02. A Case of Persistent Complete Response To Personalized Osimertinib and Concurrent Chemoradiation for Stage IIIC EGFRm NSCLC

EP08.02. A Case of Persistent Complete Response To Personalized Osimertinib and Concurrent Chemoradiation for Stage IIIC EGFRm NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This is a clinical case report about a 57-year-old male with stage IIIC non-small cell lung cancer (NSCLC) that had a mutation in the epidermal growth factor receptor (EGFR) gene. Typically, this type of lung cancer is treated as stage IV disease with an EGFR tyrosine kinase inhibitor. However, in this case, the patient was young and medically fit, so a more radical approach was taken to potentially achieve a curative outcome and longer survival.<br /><br />The patient received personalized therapy with the EGFR-targeting drug, osimertinib, with the intention of considering radical chemoradiation if the tumor shrank satisfactorily. After 2.5 months of osimertinib treatment, a PET/CT scan showed a significant reduction in the size and metabolic activity of the primary tumor and regional nodes. This positive response allowed for a more aggressive treatment approach using concurrent chemoradiation with intensity modulated radiation therapy and weekly paclitaxel/carboplatin for 7 weeks. Osimertinib was temporarily withheld before and during the chemoradiation to minimize the risk of complications.<br /><br />The patient experienced only grade 1 radiation pneumonitis, which resolved within 6 months of completing the treatment. Follow-up scans at 2 and 6 months after the chemoradiation showed a persistent complete response. At 1.2 years after completing the treatment, the patient was still receiving osimertinib and remained in complete response.<br /><br />This case suggests that frequent surveillance and personalized therapy with osimertinib can lead to effective treatment and durable control in unresectable stage III EGFR-mutant NSCLC. The radical treatment approach in this case resulted in a complete response, indicating the potential for curative outcomes in young and medically fit patients with advanced NSCLC.

Asset Subtitle

Victor Ho Fun Lee

Meta Tag

Speaker Victor Ho Fun Lee

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

clinical case report

57-year-old male

stage IIIC non-small cell lung cancer

NSCLC

mutation

epidermal growth factor receptor

EGFR gene

osimertinib

chemoradiation

curative outcome